ClinicalTrials.gg
TerminatedNCT06939816MASHUpdated Apr 23, 2026

Vonafexor in Patients With Impaired Renal Function and Suspected MASH (Metabolic Dysfunction-associated Steatohepatitis)

A Phase 2 interventional study of Vonafexor low dose and Vonafexor high dose in Chronic Kidney Disease Stage 2, Chronic Kidney Disease Stage 3 and Metabolic Dysfunction-Associated Steatohepatitis, sponsored by Enyo Pharma. Terminated at 1 site in Germany. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-23.

Sponsored by Enyo Pharma · Phase 2, Interventional, and Treatment

Why this study was terminated
Pilot cohort (n=10) yielded useful insights but data remains exploratory due to limited sample size. Study stopped due to strategic reprioritization.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 232 studies in Renal Insufficiency, Chronic with a site in Germany — 26 open to participants now, 43 under way, 19 of them phase 3. Renal Insufficiency, Chronic · Germany.

Enrollment
174th of 183
10 · median 140
Started
2025
with 11 others
Phase 2
40 of 232
none open now
Registered
216th of 232
by date

Among the 232 studies in Renal Insufficiency, Chronic with a site in Germany, this one is the 174th largest by enrollment of the 183 interventional ones that give a count, is one of 12 that started in 2025, is one of 40 in phase 2, and was the 216th registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

26 of the 232 studies in Renal Insufficiency, Chronic with a site in Germany are open now. Recruiting first, the newest first:

21 more — sign in →

All 26 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 232 studies in Renal Insufficiency, Chronic with a site in Germany, or all of them as a file.
02

Study summary

This study is designed to establish the effect of 2 doses of vonafexor on the kidney. This will be investigated in subjects with mild or moderate reduced estimated glomerular filtration rate (eGFR) and suspected MASH. In addition, the non-invasive multiparametric magnetic resonance imaging assessment of functional and structural changes in the kidney and in the liver will be investigated.

Read the detailed description

This is a phase 2, open-label, two-dose, randomized, parallel arms, single center study where subjects are participating for up to 32 weeks:

  • Screening: 4 weeks
  • Treatment: 16 weeks
  • Follow-up: 12 weeks
03

Conditions studied

  • Chronic Kidney Disease Stage 2
  • Chronic Kidney Disease Stage 3
  • Metabolic Dysfunction-Associated Steatohepatitis

Keywords

  • CKD
  • Chronic Kidney Disease
  • MASH
  • Metabolic Dysfunction-Associated Steatohepatitis
  • Kidney function
  • eGFR
  • estimated Glomerular function rate
  • mGFR
  • measured Glomerular function rate
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed and dated obtained before any trial-related activities
  • Male or female subject.
  • Age between 18 and 75 years, both inclusive.
  • Overweight or obesity ( BMI ≥ 25.0 kg/m2 and ≤ 45.0 kg/m2) with or without type 2 diabetes mellitus (T2DM with an ≤ 9.5%).
  • ≥ 30 and \< 90 (mL/min/1.73 m²).
  • Presumed mild to higher liver fibrosis as shown by a FIBROTEST score ≥ 0.28 and/or FIB-4 score ≥ 1.3.

Exclusion criteria

Exclusion Criteria:

  • Known or suspected to IMP or any of the or to any component of the IMP formulation.
  • Previous participation in this trial. Participation is defined as randomised.
  • Receipt of any medicinal product in clinical development within 30 days or at least 5 half-lives of the related substances and their metabolites (whichever is longer) before randomisation in this trial.
  • History of multiple and/or severe allergies to drugs including contrast media or foods or a history of severe anaphylactic reaction.
  • Known non-MASH liver disease.
  • History or presence of cirrhosis (evidenced on imaging or by histology, or liver decompensation, including ascites, hepatic encephalopathy, or presence of esophageal varices).
  • Total body weight loss of >5% within 6 months prior to screening.
  • If female, pregnancy or breast-feeding.
  • Women of who are not using a highly effective method and whose male partner is not using a highly effective contraceptive method for the entire study duration and for at least 6 weeks after last dosing
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Vonafexor low dose

    Vonafexor low dose 1 tablet per day

    Drug: Vonafexor low dose

  • Experimental
    Vonafexor high dose

    Vonafexor high dose 1 tablet per day

    Drug: Vonafexor high dose

Interventions

  • DrugVonafexor low dose

    Oral tablets

  • DrugVonafexor high dose

    Oral tablets

06

What researchers measure

Primary outcomes

  1. Change from baseline of mGFRiohexol at week 16

    Time frame: 16 weeks

  2. Change from baseline of eGFRcreatinine at week 16

    Time frame: 16 weeks

Secondary outcomes

  1. Vonafexor plasma concentrations

    Plasma concentrations pre-dose and post-dose which will be modelled against the MASH PopPK expected values

    Time frame: 16 weeks

  2. Change from baseline mGFRiohexol off treatment at week 24

    Time frame: 24 weeks

  3. Change from baseline of eGFRcreatinine on treatment at weeks 4, 8, 12 and off treatment at weeks 20, 24 and 28

    Time frame: 28 weeks

  4. Correlation of mGFRiohexol with eGFRcreatinine at baseline, on treatment at week 16 and off treatment at week 24

    Time frame: 24 weeks

  5. Levels and change in proteinuria in morning urine samples at baseline, on treatment at weeks 4, 8, 12, 16 with off treatment at weeks 20, 24 and 28

    Time frame: 28 weeks

  6. Treatment-emergent adverse events and serious adverse events

    Time frame: 28 weeks

Other outcomes

  1. MRI kidney biomarkers time course from baseline, to on treatment at week 16 and to off treatment at week 24

    Time frame: 24 weeks

  2. MRI liver biomarkers time course from baseline, to on treatment at week 16 and to off treatment at week 24

    Time frame: 24 weeks

  3. Liver biomarker FIB-4 changes from baseline at on treatment week 8, 16 and off treatment at week 24

    Time frame: 24 weeks

07

Study locations

1 site
  • Profil Institut für Stoffwechselforschung GmbH
    Neuss, 41460, Germany
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data that underline published results might be shared upon request with researchers who provide a methodologically sound proposal and to achieve objectives as set in the approved proposal. IPD will be shared deidentified and from 3 months and ending 5 years following article publication.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2025 to primary completion in Dec 2025, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2025
First posted
Apr 23, 2025
StartActual
Jul 1, 2025
Primary completionActual
Dec 22, 2025
CompletionActual
Mar 13, 2026
Last update
Apr 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06939816
Lead sponsor
Enyo Pharma
Responsible party
Sponsor
First posted
Apr 23, 2025
Start date
Jul 1, 2025
Primary completion
Dec 22, 2025
Completion
Mar 13, 2026
Last update
Apr 23, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion